悦康药业：YKYY018雾化吸入剂获临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical (688658) has received approval from the National Medical Products Administration for two clinical trial notifications regarding the YKYY018 aerosol inhalation agent for post-exposure prophylaxis and treatment of RSV infection [1] Group 1 - The company's wholly-owned subsidiary, Beijing Yuyuan Kete Pharmaceutical Technology Co., Ltd., will conduct Phase I clinical trials for YKYY018 [1] - The approved indications include use after exposure to respiratory syncytial virus (RSV) patients and for the treatment of RSV infections [1]